Smoldering myocarditis following immune checkpoint blockade

Journal for ImmunoTherapy of Cancer

Volumn 5, Issue 1, 2017, Pages

  Norwood, Timothy G ^a   Westbrook, Brian C ^a   Johnson, Douglas B ^b   Litovsky, Silvio H ^a   Terry, Nina L ^c   McKee, Svetlana B ^c   Gertler, Alan S ^c   Moslehi, Javid J ^d   Conry, Robert M ^c  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; Cardio oncology; Cardiotoxicity; Immune checkpoint blockade; Ipilimumab; Melanoma; Myocarditis; Nivolumab; Troponin

Indexed keywords

CHECKPOINT KINASE INHIBITOR; CREATINE KINASE; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IPILIMUMAB; METHYLPREDNISOLONE; NIVOLUMAB; ONDANSETRON; PREDNISONE; PROTON PUMP INHIBITOR; TROPONIN I;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; ELECTRIC CONDUCTIVITY; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFLAMMATION; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPHOCYTE COUNT; MIDDLE AGED; MYOCARDITIS; MYOSITIS; NAUSEA; NECK SWELLING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RHABDOMYOLYSIS; SENTINEL LYMPH NODE METASTASIS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SYMPATHETIC BLOCKING; THYROID HORMONE RELEASE; CELLULAR IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; MALE; PATHOLOGY;

FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MALE; MYOCARDITIS;

EID: 85034637551     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-017-0296-4     Document Type: Article

References (18)

1. Harris SJ, Brown J, Lopez J, et al. Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med. 2016;13:171-93.
2. Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749-55.
3. Laubli H, Balmelli C, Bossard M, et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3:11.
4. Heinzerling L, Ott PA, Hodi S, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50.
5. Makaryus AN, Makaryus MN, Hassid B. Falsely elevated cardiac troponin I levels. Clin Cardiol. 2007;30:92-4.
6. Gaborit F, Bosselmann H, Tonder N, et al. Association between left ventricular global longitudinal strain and natriuretic peptides in outpatients with chronic systolic heart failure. BMC Cardiovasc Disord. 2015;15:92.
7. Wang DY, Okoye GD, Neilan TG, et al. Cardiovascular toxicities associated with cancer Immunotherapies. Curr Cardiol Rep. 2017;19:21.
8. Rose NR. Viral myocarditis. Curr Opin Rheumatol. 2016;28:383-9.
9. Disertori M, Mase M, Ravelli F. Myocardial fibrosis predicts ventricular tachyarrhythmias. Trends Cardiovasc Med. 2017;27:363-72.
10. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8:e53745.
11. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the heart failure Association of the European Society of cardiology. J Am Coll Cardiol. 2007;50:1914-31.
12. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol. 1987;18:619-24.
13. Love VA, Grabie N, Duramad P, et al. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res. 2007;101:248-57.
14. Lucas JA, Menke J, Rabacal WA, et al. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol. 2008;181:2513-21.
15. Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9:1477-83.
16. Tarrio ML, Grabie N, Bu DX, et al. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol. 2012;188:4876-84.
17. Grabie N, Gotsman I, DaCosta R, et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation. 2007;116:2062-71.
18. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138:807-11.